Attached files

file filename
8-K - CURRENT REPORT - Adamis Pharmaceuticals Corpadamis-8k_033011.htm
EX-10.1 - FORM OF AMENDMENT TO 10% SENIOR SECURED CONVERTIBLE NOTES - Adamis Pharmaceuticals Corpex-10_1.htm
 


 
 
Exhibit 10.2
 
AMENDMENT TO ADAMIS PHARMACEUTICALS CORPORATION
 
CONVERTIBLE PROMISSORY NOTE
 
Adamis Pharmaceuticals Corporation, a Delaware corporation, and The G-Max Trust (the “Lender”), hereby agree, effective as of March 30, 2011 to amend the Convertible Promissory Note issued to Lender on December 29, 2009 by extending the Maturity Date of the Note from March 31, 2011 to June 30, 2011.
 
In the event of any inconsistency between the terms of this Amendment and the terms of the Note, the terms of this Amendment shall control.  Except to the extent expressly amended pursuant to this Amendment, the terms and provisions of the Note, as amended, shall remain in full force and effect without modification.  Capitalized terms used herein but not defined herein shall have the meanings ascribed to those terms in the Note.  This Amendment may be executed in one or more counterparts, each of which shall be an original and all of which shall together constitute one and the same document.  This Amendment shall be governed by the laws of the State of California, notwithstanding its conflict of laws provisions.
 

 
[SIGNATURE PAGE TO FOLLOW]
 
 
 

 
 
IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible Promissory Note as of the date first above written.
 
LENDER:
 
THE G-MAX TRUST
     
     
By:
/s/ Christof Boo 
 
 
Christof Boo
 
Its:
Trustee
 
     
     
By: /s/ Franchesca Boo      
  Franchesca Boo  
Its: Trustee  
 
 
 
ADAMIS PHARMACEUTICALS CORPORATION:
     
     
By:
/s/Dennis J. Carlo  
 
 
Dennis J. Carlo
 
Its:
Chief Executive Officer
 
     



[SIGNATURE PAGE TO
AMENDMENT TO 10% SENIOR SECURED CONVERTIBLE NOTE]